Methods and pharmaceutical compositions for the treatment of hiv-1 infections
OwnerJean-luc Perfettini, Guido Kroemer +2inventors
InventorsJean-luc Perfettini, Guido Kroemer, Marie-Lise Gougeon, Mauro Placentini
Life of this patent
Estimating the term…
Abstract
The present invention provides methods and compositions (such as pharmaceutical compositions) for treating or preventing human immunodeficiency virus type 1 (HIV-1) infection. More particularly, the present invention relates to a blocking agent of a component of the purinergic signalling pathway selected from the group consisting of pannexin 1, ATP or P2Y2 receptor for use in the treatment or prevention of HIV-1 infection.
Claims11
1-8. (canceled)
A method for screening a drug for the treatment or prevention of HIV-1 infection comprising the steps of:
- a) providing a candidate compound, and
- b) determining whether said candidate compound is a P2Y2 antagonist or a pannexin 1 antagonist.
(canceled)
A method of treating or preventing HIV-1 infection in a subject in need thereof, comprising
- administering to the subject a therapeutically effective amount of a blocking agent that blocks a component of the purinergic signaling pathway, wherein the component is selected from the group consisting of pannexin 1, ATP and P2Y2 receptor.
A method of determining whether or not a subject is at high risk of contracting HIV-1, comprising
- obtaining a biological sample from the subject,
- detecting in the biological sample the presence of a mutation in the P2Y2 receptor or in pannexin 11, wherein the mutation leads to a high risk of contracting HIV-1
- and, if the mutation is present in the P2Y2 receptor or in pannexin 11, then concluding that the subject is at high risk of contracting HIV-1;
- or
- if the mutation is not present in the P2Y2 receptor or pannexin 11, then concluding that the subject is not at high risk of contracting HIV-1.
Dependencies are inferred from the claim text.